QPCT regulation by CTCF leads to sunitinib resistance in renal cell carcinoma by promoting angiogenesis.
Int J Oncol
; 59(1)2021 07.
Article
en En
| MEDLINE
| ID: mdl-34036385
ABSTRACT
Sunitinib is widely used as a firstline treatment for advanced renal cell carcinoma (RCC). However, a number of patients with RCC who receive sunitinib develop drug resistance; and the biological mechanisms involved in resistance to sunitinib remain unclear. It has previously been suggested that the protein glutaminylpeptide cyclotransferase (QPCT) is closely related to sunitinib resistance in RCC. Thus, in the present study, in order to further examine the molecular mechanisms responsible for sunitinib resistance in RCC, sunitinibnonresponsive and responsive RCC tissue and plasma samples were collected and additional experiments were performed in order to elucidate the molecular mechanisms responsible for sunitinib resistance in RCC. The upstream and downstream regulatory mechanisms of QPCT were also evaluated. On the whole, the data from the present study suggest that QPCT, CCCTCbinding factor (CTCF) and phosphatidylinositol4,5bisphosphate 3kinase catalytic subunit alpha (PIK3CA) may be used as targets for predicting, reversing and treating sunitinibresistant RCC.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Carcinoma de Células Renales
/
Resistencia a Antineoplásicos
/
Aminoaciltransferasas
/
Fosfatidilinositol 3-Quinasa Clase I
/
Factor de Unión a CCCTC
/
Sunitinib
/
Neoplasias Renales
Tipo de estudio:
Prognostic_studies
Límite:
Animals
/
Humans
/
Male
Idioma:
En
Revista:
Int J Oncol
Asunto de la revista:
NEOPLASIAS
Año:
2021
Tipo del documento:
Article